Latest Boehringer Ingelheim Stories
First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human
Idarucizumab being evaluated to specifically reverse the anticoagulant effect of PRADAXA RIDGEFIELD, Conn., June 26, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S.
Nation’s Premier Annual Physical Activity and Hispanic Family Health Celebration – Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH, a German pharmaceutical company, recently announced a settlement for approximately 4,000 claims related to injuries and deaths caused by the blood thinner Pradaxa.
German drugmaker Boehringer Ingelheim has offered to settle almost 4,000 Pradaxa lawsuits in the United States.
German pharmaceutical company Boehringer Ingelheim GmbH has agreed to settle nearly 4,000 claims against the drug company for injuries and deaths caused by the blood thinner Pradaxa.
BURLINGTON, ON, June 19, 2014 /CNW/ - Results from a Phase III 52 week study, show tiotropium (delivered via Respimat(®)*)5µg, a once-daily long-acting anticholinergic bronchodilator, is efficacious
-- No additional clinical trials requested by the FDA RIDGEFIELD, Conn. and INDIANAPOLIS, June 17, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
-- In a two-year study, empagliflozin as add-on to metformin demonstrated significantly greater decreases in A1C (blood glucose), body weight and blood pressure compared with glimepiride as add-on
- One who brings meat to the table; hence, in some countries, the official title of the grand master or steward of the king's or a nobleman's household.